论文部分内容阅读
目的:观察罗格列酮治疗顽固性高血压的临床疗效。方法:顽固性高血压61例,随机分为对照组和治疗组,对照组口服尼群地平片10mg,tid;卡托普利片25mg,tid;吲哒帕胺片2.5mg,qd;拉贝洛尔片100mg,bid,3d后,200mg,bid维持;治疗组在对照组的治疗基础上加服罗格列酮片4mg,qd。2组均治疗3个月,每个月随访2次。于治疗前后,观察胰岛素抵抗指数(HOMA-IR)及血压变化情况。结果:2组患者治疗3个月后,血压均明显下降(P<0.05),治疗组较对照组下降更显著(P<0.01);对照组治疗前后HOMA-IR变化差异无统计学意义(P>0.05),治疗组治疗后下降较明显(P<0.05)。结论:罗格列酮可用于顽固性高血压的治疗。
Objective: To observe the clinical effect of rosiglitazone on refractory hypertension. Methods: 61 cases of refractory hypertension were randomly divided into control group and treatment group. The control group was given nitrendipine tablets 10mg, tid; captopril tablets 25mg, tid; indapamide tablets 2.5mg, qd; Loroprazole 100mg, bid, 3d, 200mg, bid to maintain; treatment group in the control group based on the treatment plus service plus rosiglitazone tablets 4mg, qd. Two groups were treated for 3 months, followed up twice a month. Before and after treatment, observed insulin resistance index (HOMA-IR) and blood pressure changes. Results: After 3 months of treatment, the blood pressure decreased significantly in both groups (P <0.05), and the treatment group decreased more significantly than the control group (P <0.01). There was no significant difference in HOMA-IR between the two groups before and after treatment (P > 0.05), the treatment group decreased more obviously after treatment (P <0.05). Conclusion: Rosiglitazone can be used to treat refractory hypertension.